31
total announcements
ALIVUS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹16,550 Cr
P/E (TTM)
27.5
P/E (Forward)
21.5
EPS (TTM)
₹49.03
52W Low
₹819.00
52W High
₹1,493.80
Dividend Yield
0.37%
Beta
0.07
Price / Book
5.0
Debt / Equity
1.7
Revenue (TTM)
₹2,590 Cr
Gross Margin
59.42%
Operating Margin
29.84%
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced its 15th Annual General Meeting (AGM) to be held on September 8, 2026, through video conferencing. The company has also recommended a final dividend of Rs. 5.00 per equity share for the financial year ended March 31, 2026, subject to approval by shareholders.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has uploaded the audio recording of its Q1 FY2027 Earnings Call on its website.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has approved the allotment of 32,000 equity shares to eligible employees under the 'Employee Stock Option Scheme, 2021'. The paid-up share capital of the company has increased to Rs. 24,55,42,896.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has released its Q1 FY 2026-27 investor presentation, highlighting a positive start to the year with strong execution and accelerating traction in the non-GPL business. The company expects revenue growth of 10% - 12% in FY27, while sustaining EBITDA margins in the 30%–32% range.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd reported Q1FY27 results with revenue growth of 6.4% YoY, EBITDA growth of 29.1% YoY, and PAT growth of 31.8% YoY. The company achieved its highest-ever PAT margin of 25.0% and EBITDA margin of 36.6%. The company also announced plans for capacity expansion and pipeline development.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations at Rs. 6,404.14 million, a decrease of 6.3% from the previous quarter. Net profit for the period was Rs. 1,600.76 million, with earnings per equity share at Rs. 13.04.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations at ₹6,404.14 crore and net profit for the period at ₹1,600.76 crore.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced an earnings call for Q1 FY2026-27 on July 31, 2026, to discuss its financial performance.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced the closure of the trading window from July 1, 2026 to August 1, 2026, for the purpose of approving unaudited financial results for the quarter ended June 30, 2026.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has scheduled a Board Meeting on July 30, 2026, to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Limited) has announced an institutional investor meeting in the form of a plant visit scheduled for June 29, 2026, at its Ankleshwar, Gujarat facility. This visit, which may be a group or one-on-one meeting, is to facilitate engagement with institutional investors. The company noted that the schedule and mode could change due to exigencies.